Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)18.44
  • Today's Change0.44 / 2.44%
  • Shares traded521.14k
  • 1 Year change-33.02%
  • Beta0.8767
Data delayed at least 15 minutes, as of Feb 09 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.

  • Revenue in USD (TTM)441.63m
  • Net income in USD-206.81m
  • Incorporated2013
  • Employees1.87k
  • Location
    Zai Lab LtdBuilding B, 899 Halei Road, PudongSHANGHAI 201203ChinaCHN
  • Phone+86 2 161632588
  • Fax+86 2 161632570
  • Websitehttps://www.zailaboratory.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Immunocore Holdings PLC - ADR379.59m-29.23m1.68bn493.00------4.43-0.5866-0.58667.49--0.34710.53365.44769,959.40-2.67-17.90-3.34-23.2699.29---7.70-53.745.97--0.4975--24.3756.777.60---1.06--
Harrow Inc250.04m-4.99m1.76bn382.00--37.38128.487.03-0.1522-0.15226.701.270.69985.533.81654,560.20-1.40-9.11-1.80-10.8974.5672.78-1.99-14.342.521.110.8388--53.3231.2928.39--92.29--
Vericel Corp258.72m13.08m1.79bn357.00189.325.5777.326.930.18720.18724.866.370.61334.004.75724,697.503.10-1.033.46-1.1873.8169.105.06-1.614.47--0.002--20.1015.02425.64--89.53--
ANI Pharmaceuticals Inc826.88m34.14m1.81bn897.0049.273.5713.842.181.631.6340.8922.510.61352.183.68921,828.303.01-2.993.63-3.4961.1458.844.91-6.122.043.830.5508--26.2024.36-230.19--19.60--
Aurinia Pharmaceuticals Inc265.81m77.84m1.92bn300.0025.905.2419.697.210.5610.5611.882.770.49370.70467.91--14.46-18.8416.88-20.9788.93--29.28-72.475.17--0.1645--33.97274.78107.37--22.71--
Sarepta Therapeutics Inc2.41bn-271.51m1.92bn1.37k--1.45--0.7949-3.19-3.1922.0912.600.68060.69775.811,759,268.00-7.66-12.82-9.92-15.4776.2585.53-11.25-37.161.79--0.4395--52.9737.94143.89--18.57--
Perrigo Company PLC4.28bn-29.20m1.97bn8.38k--0.44316.510.4603-0.2128-0.376431.0032.310.40232.345.75511,015.60-0.2743-0.7059-0.3124-0.808235.4634.96-0.682-1.761.442.410.4505---6.062.48-3,552.27---16.2318.65
Zai Lab Ltd - ADR441.63m-206.81m2.03bn1.87k--2.68--4.60-1.94-1.944.116.870.41193.196.53236,291.60-19.29-33.80-27.61-39.1261.5264.07-46.83-186.772.68--0.2108--49.5998.3823.17--32.19--
Ocular Therapeutix Inc51.95m-265.94m2.05bn325.00--3.11--39.51-1.44-1.440.27753.030.08211.991.65159,849.20-42.01-38.63-45.31-43.3187.3590.18-511.90-229.5415.32--0.0983---18.4724.45-37.43--70.20--
Organon & Co6.30bn501.00m2.06bn10.00k4.112.272.440.32641.921.9224.203.480.47911.973.98630,100.003.8111.524.8114.9455.0462.307.9520.241.202.500.906916.022.24-3.81-15.54-23.5430.71--
Phibro Animal Health Corp1.46bn92.09m2.10bn2.48k22.996.3214.711.442.262.2635.888.211.092.097.18591,646.406.843.898.474.8732.5631.146.293.691.224.390.687552.0227.3710.121,897.687.542.380.00
Avadel Pharmaceuticals PLC (ADR)248.52m-278.00k2.12bn188.00--21.40624.518.54-0.0055-0.00552.531.011.391.116.251,321,899.00-0.1554-42.00-0.2203-50.5391.09---0.1119-194.152.37-0.51260.2618--504.7923.3569.53------
Harmony Biosciences Holdings Inc825.94m185.68m2.14bn246.0011.682.5610.192.593.183.1814.1314.500.773226.709.07--17.3815.6421.2019.1377.7079.7822.4820.613.72--0.16790.0022.80160.1812.91---56.63--
Ultragenyx Pharmaceutical Inc630.60m-579.83m2.30bn1.29k--251.45--3.65-5.94-5.946.460.0950.46222.026.13487,324.60-42.50-33.04-55.49-38.8484.6991.29-91.95-127.451.74-17.520.9809--29.0140.126.17---4.24--
Data as of Feb 09 2026. Currency figures normalised to Zai Lab Ltd's reporting currency: US Dollar USD

Institutional shareholders

20.50%Per cent of shares held by top holders
HolderShares% Held
Capital Research & Management Co. (World Investors)as of 30 Sep 20256.08m5.43%
Fidelity Management & Research Co. LLCas of 30 Sep 20254.11m3.67%
ClearBridge Investments LLCas of 30 Sep 20253.52m3.14%
Janus Henderson Investors US LLCas of 30 Sep 20252.04m1.83%
UBS Securities LLCas of 31 Dec 20251.78m1.59%
BAMCO, Inc.as of 30 Sep 20251.37m1.23%
Wellington Management Co. LLPas of 30 Sep 20251.29m1.15%
T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2025948.67k0.85%
Citadel Advisors LLCas of 30 Sep 2025935.72k0.84%
Adar1 Capital Management LLCas of 30 Sep 2025868.78k0.78%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.